Hoping to capitalize on a tsunami of interest in GLP-1 agonists for weight loss, Structure Therapeutics (Nasdaq: GPCR) has now published Phase IIa data for its oral candidate, but investors are not happy.
Shares in the company fell markedly following the release of a comprehensive development program update for its therapy, coded GSBR-1290.
The data show a significant impact on both HbA1c and weight reduction, compared to placebo.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze